Abstract: A device may comprise security processing units (SPUs) including a SPU to receive a session request. The SPU may identify global counter information and update counter information. The global counter information may include a global counter identifier and a global counter value. The update counter information may include an update counter identifier and an update counter value. The SPU may identify a global limit associated with the global counter, may determine that the global limit has not been met, and may cause the session to be created. The SPU may create a modified global counter value. The SPU may create a modified update counter value. The SPU may determine that a local update message is required based on the modified update counter value, and may provide the local update message to another SPU. The local update message may include the global counter identifier and the modified global counter value.

Abstract: Compositions and methods are provided for diagnosis, prognosis and treatment of AR-related diseases, such as prostate diseases, such as prostate cancer, breast cancer, and many other diseases. In particular, a novel and clinically relevant mutation at position 877 of the androgen receptor (AR) has been identified. Drug sensitivity can be predicted and therapeutic regimens can be planned on the basis of the presence or absence of this mutation. Polypeptides comprising, antibodies to, and polynucleotides encoding the mutant AR can be used to identity novel treatments. A double mutation in AR at positions 742 and 878 is also shown to be useful for patient stratification.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: Cutting fluids for brittle materials, e.g., silicon ingot, comprise, in weight percent: A. 70-99% polyalkylene glycol (PAG), e.g., polyethylene glycol; B. 0.01-10% PAG-grafted polycarboxylate; and C. 0-30% water. These cutting fluids are used with abrasive materials, e.g., silicon carbide (SiC), to form cutting slurries. The slurry is sprayed on the cutting tool, e.g., a wire saw, to cut a brittle work piece, e.g., a silicon ingot.

Abstract: A method for detecting a dissolution rate of a preparation containing colloidal bismuth pectin includes steps of: according to “Pharmacopoeia of the People's Republic of China, 2010 Edition, Volume 2, Appendix XC”, dispersing the preparation containing the colloidal bismuth pectin into dissolution medium, and directly obtaining dissolution liquid; adding a protonic acid dissociation agent into the dissolution liquid until a hydrogen ion concentration reaches 0.8-1.2 mol/L; centrifuging for separating a supernatant; coloring the supernatant by adding a chromogen solution of citric acid or ascorbic acid and potassium iodide to obtain a test solution; calculating a dissolution amount, which is accounted by bismuth, of the colloidal bismuth pectin with a spectrophotometry method. The method of the present invention well detects dissolution curves and rates of the colloidal bismuth pectin in the preparation thereof, satisfying quality control requirements.

Abstract: Provided is a method for measuring the bismuth content in a colloidal bismuth pectin or a colloidal bismuth pectin-contained preparation. A protonic acid is used to dissociate bismuth from a colloidal bismuth pectin, the principle of the characteristic reaction between bismuth and potassium iodide to produce yellow potassium bismuth iodide is used; ultraviolet-visible spectrophotometry is for measurement; an external standard method is for calculation. The method has strong specificity, a good linear relationship, high accuracy, good repeatability and high sensitivity. The method is able to act as a quality control method for bismuth in a colloidal bismuth pectin or a colloidal bismuth pectin-contained preparation to effectively control the product quality.

Abstract: A device includes a security process unit (SPU) associated with a logical ring of SPUs. The SPU receives a packet with an address associated with a malicious source, and creates, based on the packet, an entry in a data structure associated with the SPU. The entry includes information associated with the packet. The SPU provides an install message to a next SPU in the logical ring. The install message instructs the next SPU to create the entry in another data structure, and forward the install message to another SPU. The SPU receives the install message from a last SPU, and sets a state of the entry to active in the data structure based on receiving the install message from the last SPU. The SPU performs a particular action on another packet, associated with the malicious source, based on the setting the state of the entry to active.

Abstract: A water-based cutting fluid that comprises water and a water-soluble polyalkylene glycol (PAG) having cloud point from 30° C. to 80° C. The cutting fluid is water-based, i.e., it comprises at least 50 percent by weight (wt %) water. The cutting fluids are well suited for use with diamond wiresaws for the cutting of silicon ingots. The fluids exhibit one or more of low hydrogen generation, no wafer cleaning issues, good lubricity, good cooling efficiency, good swarf suspension and dispersion, low foaming, are generally non-sensitive to metal ions, and are nonflammable.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: Disinfectant compositions include 0.001 to 10% by weight of hydrogen peroxide or a hydrogen peroxide source based on the total weight of the composition; 0.001 to 20% by weight of at least one amphoteric surfactant based on the total weight of the composition; and 0.001 to 15% by weight of at least one alkali metal or alkaline earth metal salt of a cyclic or heterocyclic aromatic compound comprising at least one hydroxyl group, carboxylic group, or combination thereof based on the total weight of the composition. The disinfectant compositions are particularly effective at treating surfaces contaminated with resistant bacteria, such as Staphylococcus aureus at a fast killing rate.

Abstract: A device includes a security process unit (SPU) associated with a logical ring of SPUs. The SPU receives a packet with an address associated with a malicious source, and creates, based on the packet, an entry in a data structure associated with the SPU. The entry includes information associated with the packet. The SPU provides an install message to a next SPU in the logical ring. The install message instructs the next SPU to create the entry in another data structure, and forward the install message to another SPU. The SPU receives the install message from a last SPU, and sets a state of the entry to active in the data structure based on receiving the install message from the last SPU. The SPU performs a particular action on another packet, associated with the malicious source, based on the setting the state of the entry to active.

Abstract: A dispersion preparation containing colloidal bismuth pectin is provided. 1 g is adopted as a unit for the preparation. Each unit of the preparation includes: 44.0 to 900.0 mg of colloidal bismuth pectin, 1.0-500 mg of a penetration enhancer, 2.0-312.5 mg of acid-source pore forming agent, 2.0-250.0 mg of alkali-source pore forming agent and 1.0-400.0 mg of a disintegrating agent.

Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

Abstract: Disinfectant compositions include 0.001 to 10% by weight of hydrogen peroxide or a hydrogen peroxide source based on the total weight of the composition; 0.001 to 20% by weight of at least one amphoteric surfactant based on the total weight of the composition; and 0.001 to 0.8% by weight of at least one alkali metal or alkaline earth metal salt of a cyclic or heterocyclic aromatic compound comprising at least one hydroxyl group, carboxylic group, or combination thereof based on the total weight of the composition. The disinfectant compositions are particularly effective at treating surfaces contaminated with resistant bacteria, such as Staphylococcus aureus at a fast killing rate.

Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: Email tags are described. In embodiments, email messages are received for distribution to client devices that correspond to respective recipients of the email messages. Email routing decisions are applied to route an email message to an email folder for a recipient of the email message, where the email folder may include an email inbox, a junk folder, or a user-created folder. The email message is then tagged with an email tag to generate a tagged email message. The email tag includes a routing description that indicates why the email message was routed to the particular email folder.

Abstract: A stable, aqueous, liquid composition comprises both an enzyme and a peroxide or peroxide source. The composition contains a compatibilizer package having at least one compound chosen from enzyme stabilizers and peroxide stabilizers. The compatibilizer package maintains the activity of the enzyme and the concentration of the peroxide. A composition comprising peroxide or a peroxide source and a compatibilizer package is also disclosed.

Abstract: Email tags are described. In embodiments, email messages are received for distribution to client devices that correspond to respective recipients of the email messages. Email routing decisions are applied to route an email message to an email folder for a recipient of the email message, where the email folder may include an email inbox, a junk folder, or a user-created folder. The email message is then tagged with an email tag to generate a tagged email message. The email tag includes a routing description that indicates why the email message was routed to the particular email folder.